The Medicines Patent Pool (MPP) said it signed an extension of its licensing agreement with biopharmaceutical company Bristol-Myers Squibb (BMS) to further increase access to atazanavir (ATV), part of the World Health Organization-preferred second-line treatment for adults and children.
The MPP is a United Nations-backed public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatments in low and middle income countries.
Announced during an MPP-jointly hosted satellite at the 9th International AIDS Society Conference on HIV Science in Paris, the amendment adds 12 countries to the 110 included in the original 2013 agreement.
The additional countries are: Algeria, Cook Islands, Egypt, Equatorial Guinea, Indonesia, Malaysia, Morocco, Niue, the Philippines, Tunisia, Ukraine and Vietnam.
“Our ATV licence has already demonstrated results for communities battling resistance to current regimens in low and middle income countries,” said Greg Perry, Executive Director of the MPP.
“We are pleased to work with long-term partner BMS to broaden access to an important second-line option for many more people living with HIV.”
Amadou Diarra, Head of Global Policy, Advocacy & Government Affairs, Bristol-Myers Squibb, said: “Our work with the MPP is an important part of our commitment to access through multi-faceted approaches that help ensure innovative medicines such as atazanavir are available to patients all around the world.
“We are pleased by the continuing progress made to that end through our licensing agreements with the MPP.”